These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 7809080

  • 1. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
    Chiu MI, Katz H, Berlin V.
    Proc Natl Acad Sci U S A; 1994 Dec 20; 91(26):12574-8. PubMed ID: 7809080
    [Abstract] [Full Text] [Related]

  • 2. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
    Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT.
    J Biol Chem; 1995 Jan 13; 270(2):815-22. PubMed ID: 7822316
    [Abstract] [Full Text] [Related]

  • 3. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
    Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH.
    Cell; 1994 Jul 15; 78(1):35-43. PubMed ID: 7518356
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
    Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL.
    Nature; 1994 Jun 30; 369(6483):756-8. PubMed ID: 8008069
    [Abstract] [Full Text] [Related]

  • 9. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.
    Chen J, Zheng XF, Brown EJ, Schreiber SL.
    Proc Natl Acad Sci U S A; 1995 May 23; 92(11):4947-51. PubMed ID: 7539137
    [Abstract] [Full Text] [Related]

  • 10. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity.
    Cardenas ME, Heitman J.
    EMBO J; 1995 Dec 01; 14(23):5892-907. PubMed ID: 8846782
    [Abstract] [Full Text] [Related]

  • 11. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
    Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, Faucette L, Eng WK, Johnson RK, Livi GP.
    Mol Cell Biol; 1993 Oct 01; 13(10):6012-23. PubMed ID: 8413204
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface.
    Luengo JI, Yamashita DS, Dunnington D, Beck AK, Rozamus LW, Yen HK, Bossard MJ, Levy MA, Hand A, Newman-Tarr T.
    Chem Biol; 1995 Jul 01; 2(7):471-81. PubMed ID: 9383449
    [Abstract] [Full Text] [Related]

  • 14. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.
    Choi J, Chen J, Schreiber SL, Clardy J.
    Science; 1996 Jul 12; 273(5272):239-42. PubMed ID: 8662507
    [Abstract] [Full Text] [Related]

  • 15. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.
    Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL.
    Cell; 1995 Jul 14; 82(1):121-30. PubMed ID: 7606777
    [Abstract] [Full Text] [Related]

  • 16. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression.
    Vilella-Bach M, Nuzzi P, Fang Y, Chen J.
    J Biol Chem; 1999 Feb 12; 274(7):4266-72. PubMed ID: 9933627
    [Abstract] [Full Text] [Related]

  • 17. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin.
    Cardenas ME, Zhu D, Heitman J.
    Curr Opin Nephrol Hypertens; 1995 Nov 12; 4(6):472-7. PubMed ID: 8591053
    [Abstract] [Full Text] [Related]

  • 18. Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast.
    Alarcon CM, Heitman J, Cardenas ME.
    Mol Biol Cell; 1999 Aug 12; 10(8):2531-46. PubMed ID: 10436010
    [Abstract] [Full Text] [Related]

  • 19. Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast.
    Alarcon CM, Cardenas ME, Heitman J.
    Genes Dev; 1996 Feb 01; 10(3):279-88. PubMed ID: 8595879
    [Abstract] [Full Text] [Related]

  • 20. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.
    Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE.
    Eur J Immunol; 1995 Feb 01; 25(2):563-71. PubMed ID: 7533090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.